Written by Private MD Labs Medical Writing Team • Last Updated: September 8, 2025
Melanoma is a serious form of skin cancer that is primarily diagnosed through tissue biopsy and histological examination. While there is no blood test to diagnose melanoma itself, genetic testing plays a crucial role in understanding the specific characteristics of the tumor and guiding personalized treatment decisions.
This genetic test identifies mutations in the BRAF gene, which are found in approximately 50% of melanomas. The most common mutation, V600E, leads to uncontrolled cell growth and division that contributes to melanoma development. Identifying BRAF mutations is essential for determining eligibility for targeted therapies, as specific medications are designed to block the effects of these mutations and can significantly improve treatment outcomes.
After a melanoma diagnosis is confirmed through biopsy, genetic analysis of the tumor tissue becomes fundamental for determining the most effective treatment approach. Understanding the specific genetic mutations present in the melanoma helps oncologists select targeted therapies that are most likely to be successful for each individual patient.
BRAF mutations cause cells to grow and divide uncontrollably, contributing to melanoma development. When these mutations are present, targeted therapies that specifically block the mutated BRAF protein can be highly effective. This personalized approach to treatment has revolutionized melanoma care and improved outcomes for many patients.
The information here is for educational purposes only and is not a substitute for professional medical advice. Always consult with a healthcare provider for diagnosis and treatment.